Skip to main content
SpringerLink
Log in

Differences in Coronavirus disease - 19 vaccination related side effects in patients with ulcerative colitis and Crohn’s disease in Japan

  • Original Article
  • Published:
Indian Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background/Purpose of this study

It has been recommended that individuals with inflammatory bowel disease (IBD) be vaccinated against Coronavirus disease - 19 (COVID-19). Recently, we documented the incidence of side effects (SEs) after COVID-19 immunization among individuals with IBD in Japan. However, the study did not show differences between the types of IBD or the patients’ clinical backgrounds. In this survey, we aimed at investigating whether the frequency of SEs differed among patients with IBD.

Methods

A cross-sectional survey was conducted among adult patients with IBD at Kobe University between March 2022 and September 2022.

Results

Total 195 patients, including 134 with ulcerative colitis (UC) and 61 with Crohn’s disease (CD), completed the questionnaire and were included in the analysis. Of these, 92.3%, 91.3% and 44.1% received the initial, second and third dose of the COVID-19 vaccine, respectively. The frequency of local symptoms following the initial, second and third dose of the vaccine was comparable between patients with UC and CD (69.6% vs. 72.7%, 64.2% vs. 69.1% and 63.5% vs. 73.9%, respectively). Muscle pain after the initial and second doses of the COVID-19 vaccine was more common among patients treated with corticosteroids (58.1% vs. 37.6% and 60.0% vs. 31.8%, p < 0.05). Female sex, younger age and current or former smoking were associated with an increased incidence of fever or chills after the initial dose of the vaccine (p < 0.05). In contrast, corticosteroid use was identified as a factor associated with an increased incidence of muscle pain after the initial dose of vaccine (p < 0.05).

Conclusion

The use of corticosteroids could increase the risk of muscle pain following COVID-19 vaccination. Additionally, factors such as female sex, younger age and current or former smoking can affect the incidence of fever or chills. This information should encourage patients with IBD to get vaccinated against COVID-19.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Mathur A, Sahu S, Rai S, Ghoshal U, Ghoshal UC. Serological response to vaccination against coronavirus disease-19 in patients with inflammatory bowel disease. Indian J Gastroenterol. 2023;42:64–9.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Jena A, James D, Singh AK, Dutta U, Sebastian S, Sharma V. Effectiveness and durability of COVID-19 vaccination in 9447 patients with IBD: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20:1456–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39:4423–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603–15.

    Article  CAS  PubMed  Google Scholar 

  5. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384:403–16.

    Article  CAS  PubMed  Google Scholar 

  6. Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N Engl J Med. 2021;385:2348–60.

    Article  CAS  PubMed  Google Scholar 

  7. James D, Jena A, Bharath PN, et al. Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systematic review and meta-analysis. Dig Liver Dis. 2022;54:713–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Miyazaki H, Watanabe D, Ito Y, et al. Side effects of COVID-19 vaccines in patients with inflammatory bowel disease in Japan. Dig Dis Sci. 2022;68:564–70.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Gologan S, Iacob R, Iancu D, et al. Inflammatory gene expression profiles in Crohn’s disease and ulcerative colitis: a comparative analysis using a reverse transcriptase multiplex ligation-dependent probe amplification protocol. J Crohns Colitis. 2013;7:622–30.

    Article  PubMed  Google Scholar 

  10. Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis. Front Immunol. 2021;12: 714170.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Siegel CA, Melmed GY, McGovern DP, et al. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut. 2021;70:635–40.

    Article  CAS  PubMed  Google Scholar 

  12. Botwin GJ, Li D, Figueiredo J, et al. Adverse events after SARS-CoV-2 mRNA vaccination among patients with inflammatory bowel disease. Am J Gastroenterol. 2021;116:1746–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Boekel L, Kummer LY, van Dam KPJ, et al. Adverse events after first COVID-19 vaccination in patients with autoimmune diseases. Lancet Rheumatol. 2021;3:e542–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Beatty AL, Peyser ND, Butcher XE, et al. Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA Netw Open. 2021;4: e2140364.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Green MS, Peer V, Magid A, Hagani N, Anis E, Nitzan D. Gender differences in adverse events following the Pfizer-BioNTech COVID-19 vaccine. Vaccines (Basel). 2022;10:233.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Japan Society for the Promotion of Science KAKENHI Grants 22K15966

Author information

Authors and Affiliations

  1. Kobe University Graduate School of Medicine, Division of Gastroenterology, Department of Internal Medicine, 7-5-1 Kusunoki Cho, Chuo Ku, Kobe, 650-0017, Japan

    Haruka Miyazaki, Daisuke Watanabe, Yuki Ito, Sayaka Ikeda, Norihiro Okamoto, Eri Tokunaga, Yuna Ku, Makoto Ooi, Namiko Hoshi & Yuzo Kodama

Authors
  1. Haruka Miyazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daisuke Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuki Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sayaka Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Norihiro Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eri Tokunaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yuna Ku
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Makoto Ooi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Namiko Hoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yuzo Kodama
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

H.M., D.W., Y.I., S.I., N.O., E.T., Y.K., M.O., N.H. and Y.K. collected the data and wrote the manuscript.

Corresponding author

Correspondence to Daisuke Watanabe.

Ethics declarations

Conflict of interest

HM, DW, YI, SI, NO, ET, YK, MO, NH and YuK declare that they have no conflict of interest.

Ethics statement

The study was performed conforming to the Helsinki Declaration of 1975, as revised in 2000 and 2008 concerning human and animal rights, and the authors followed the policy concerning informed consent as shown on Springer.com.

Disclaimer

The authors are solely responsible for the data and the content of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, the Indian Society of Gastroenterology or printer/publishers are responsible for the results/ findings and content of this article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

12664_2023_1386_MOESM1_ESM.docx

Supplementary file1 (DOCX 16 kb) Supplementary Table. Exploration of the possible factors associated with systemic SEs subsequent to COVID-19 vaccination via implementation of a multivariate logistic regression analysis

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Miyazaki, H., Watanabe, D., Ito, Y. et al. Differences in Coronavirus disease - 19 vaccination related side effects in patients with ulcerative colitis and Crohn’s disease in Japan. Indian J Gastroenterol 42, 701–707 (2023). https://doi.org/10.1007/s12664-023-01386-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12664-023-01386-0

Keywords

Search

Navigation